IDT Australia (ASX:IDT) Debt-to-Asset : 0.14 (As of Jun. 2024)

View and export this data going back to 1991. Start your Free Trial

What is IDT Australia Debt-to-Asset?

IDT Australia's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was A$4.47 Mil. IDT Australia's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was A$0.00 Mil. IDT Australia's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was A$31.37 Mil. IDT Australia's debt to asset for the quarter that ended in Jun. 2024 was 0.14.

IDT Australia Debt-to-Asset Historical Data

The historical data trend for IDT Australia's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDT Australia Debt-to-Asset Chart

IDT Australia Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Debt-to-Asset

Get a 7-Day Free Trial

0.02

0.03

0.14

IDT Australia Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Asset	Get a 7-Day Free Trial															0.03	-	0.03	0.08	0.14

Competitive Comparison of IDT Australia's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, IDT Australia's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IDT Australia's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, IDT Australia's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where IDT Australia's Debt-to-Asset falls into.

IDT Australia Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

IDT Australia's Debt-to-Asset for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(4.468	+	0)	/	31.371
	=	0.14

IDT Australia's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(4.468	+	0)	/	31.371
	=	0.14

IDT Australia (ASX:IDT) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

IDT Australia Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of IDT Australia's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

IDT Australia Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » IDT Australia Ltd (ASX:IDT) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

45 Wadhurst Drive, Boronia, Melbourne, VIC, AUS, 3155

Website

https://www.idtaus.com.au

IDT Australia Ltd produces, develops, and supplies pharmaceutical products. It is engaged in the provision of research and development and other technical services for the pharmaceutical and allied industries. The company is involved in the manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging, and pharmacy services.